ArticleThe Journal of infectious diseases2026
Epstein-Barr Virus Antibody Response Patterns in Endemic and Nonendemic Cases of Nasopharyngeal Carcinoma.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A high-throughput Epstein-Barr virus nuclear antigen 1 (EBNA1) serology test strip for nasopharyngeal carcinoma risk screening.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) causes most nasopharyngeal carcinoma (NPC), a malignancy endemic in certain regions, presenting with nonspecific symptoms and lacking a robust minimally invasive biomarker. To assess previously developed multiplex Luminex assay EBV antibody signatures in a nonendemic population, we analyzed and compared 98 NPC sera and 142 matched controls from the nonendemic Head and Neck 5000 clinical cohort against an endemic Taiwan case-control cohort. All models, except the 2-antibody IgA panel, performed similarly, achieving 90%-99% accuracy in identifying EBV-positive NPC. Our results showed that EBV antibody panels can accurately define EBV-positive NPC regardless of endemicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.